BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE. RHEUMATOLOGY SHARED CARE GUIDELINE for DMARDs
|
|
- Barry Thompson
- 5 years ago
- Views:
Transcription
1 BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE RHEUMATOLOGY SHARED CARE GUIDELINE fr DMARDs There are currently 6 Disease-mdifying anti rheumatic drugs (DMARDs) in rutine use by the Lutn & Dunstable NHS Trust and Bedfrd Hspital Rheumatlgy Departments. Methtrexate (ral r Subcutaneus injectin) Sulfasalazine Leflunmide Azathiprine Mycphenlate Hydrxychlrquine Overarching Principles f Shared Care Guidelines The intrductin f these shared care guidelines fr cmmnly used DMARDs facilitates the fllwing aspects f patient care: Patients can be seen and initiated n the mst apprpriate DMARD treatment regimen under the care f a Rheumatlgy Specialist team. The nging rutine prescribing and bld test mnitring can be taken ver by the patient s wn GP (at a mutually acceptable time as agreed between the GP and the Specialist - typically smewhere between 4 and 12 weeks after treatment started, depending n lcal GP practice preference). GPs can cntact the Rheumatlgy Specialist team directly fr advice and supprt n an nging basis. Patients will cntinue t be reviewed by the Rheumatlgy Specialist team at scheduled ut-patient appintments (frequency will vary n an individual basis). T initiate shared care: All shared care arrangements rely upn clear cmmunicatin between the Specialist, GP and the individual patient and / r their carer. A member f the Specialist Rheumatlgy team shuld cntact the patient s GP and discuss the cncept f shared care at the pint f initiatin f DMARD therapy. If a GP is nt able t participate fully with the shared care agreement, they are under n bligatin t d s. In such an event, the ttal clinical respnsibility fr the patient fr the diagnsed rheumatlgical cnditin will remain with the Specialist team.
2 Timing f Implementatin f Shared care arrangements: Due t practical reasns, there is currently a difference in practise between BCCG and LCCG as t when GPs will cnsider accepting prescribing and bld test mnitring respnsibilities fr DMARDs. Lcal arrangements are: BCCG GPs can cnsider accepting prescribing and bld test mnitring respnsibility under shared care arrangement frm week 4 nwards (NB: This may be prir t the patient being treated with a stable dse f the chsen DMARD). LCCG GPs can cnsider accepting prescribing and bld test mnitring respnsibility under shared care arrangement nly when the patient has reached a stable maintenance dse. (NB: The time t reach a stable dse will vary depending n the DMARD chsen and individual patient factrs.) Bld Test Mnitring and Prescribing f DMARDs by GPs As part f the shared care agreement, the GP as the prescribing clinician is respnsible fr the drug and the cnsequences f its use. The GP is therefre respnsible fr checking the bld test results PRIOR t the issue f a prescriptin f the specific DMARD. (This includes checking the bld test results even if the bld tests are requested by the Specialist at any pint). In situatins when bld tests are rdered by the Specialist, the Specialist must ensure that a cpy f the results are sent t the GP (either electrnically r paper cpy) in a timely manner t enable the GP t check the results prir t issuing a prescriptin. Frequency f Bld Test Mnitring: The British Rheumatlgy Sciety (BSR) have published a guideline:- Guidelines fr diseasemdifying anti-rheumatic drug (DMARD) therapy (2017) utlining the frequency f bld test mnitring. The BSR guidelines have in general, adpted a harmnised apprach acrss the 6 DMARDs (where pssible) in rder t standardise the frequency f bld test mnitring. Details f frequency are specified in Appendix 1. NB: Patients are ften prescribed mre than ne DMARD e.g. methtrexate and sulfasalazine. In general, mnitring f patients n mre than ne DMARD shuld be based n the DMARD which requires the mst frequent mnitring. Individual Respnsibilities: Hspital Specialist Team At Initiatin f therapy phase Cntact the GP t request share care. Infrm GP that a cpy f the Rheumatlgy Shared care guideline plus the relevant DMARD drug Prescribing infrmatin sheet are dwnladable frm the GP Ref website. Cnfirm diagnsis and indicatin fr drug treatment. Assess the patient fr any c-mrbidities, including evaluatin fr respiratry disease and screening fr ccult viral infectin e.g. varicella, when chsing the mst apprpriate DMARD therapy. Discuss ptential benefits and side-effects f treatment with patient. Explain the bld test mnitring schedule and the imprtance f attending fr regular bld tests t the patient. Carry ut baseline mnitring requirements. Send a cpy f the baseline test results t the GP fr infrmatin (electrnically r paper cpy as apprpriate).
3 Hspital Specialist Team At Initiatin f therapy phase cnt. Prvide patients with the relevant advice relating t the particular DMARD(s) being initiated e.g. cntraceptin / varicella- zster immunity / alchl cnsumptin / cyttxic waste dispsal. Advise patient t infrm all healthcare prfessinals (e.g. GPs, A&E clinicians, cmmunity pharmacists) that they are taking DMARD therapy and that regular bld test mnitring is being undertaken. Advise patient t shw a cpy f the mst recent clinic letter cntaining details f their current dse t the cmmunity pharmacist when presenting a prescriptin fr DMARD therapy. Prvide patient with any relevant patient infrmatin leaflet(s) fr example: Natinal patient Safety agency (NPSA) patient infrmatin leaflet Arthritis Research UK patient infrmatin leaflet In-huse develped patient infrmatin leaflet (if applicable) Prvide patient with a patient-held mnitring & dsage recrd bklet (NPSA bklet r lcally agreed equivalent bklet) and prvide replacement bklets when required (if applicable.) NB: It has been agreed lcally that bld tests d nt need t be written in a patient-held mnitring bklet as bld test results can be accessed electrnically by lcal GPs and the Specialist Rheumatlgy Team If electrnic access is nt available, a decisin as t whether t recrd the results in the patient bklet shuld be agreed between the Specialist team/ the GP and the patient n an individual basis. Check fr pssible drug interactins with existing medicatin, befre initiating DMARD therapy. (Refer t individual SPCs / electrnic BNF) Pssible drug interactins shuld als be checked if prescribing any new medicatins r when stpping any cncurrent medicatins at any pint. Ensure that the hspital pharmacy cmputer sftware has the latest cmputer sftware updates relevant t the chsen DMARD, e.g. methtrexate alerts and prmpts. (as per NPSA advice) Initiate DMARD therapy and prescribe until the shared care agreement begins (this typically invlves the Specialist prviding the first 6 t 12 weeks (depending n BCCG LCCG cmmissining psitin) supply f medicatin and then, the GP taking ver bth prescribing and bld test mnitring respnsibilities). The initial prescriptin issued by the Specialist team shuld be fr a 6 week supply f medicatin, and any subsequent prescriptins shuld be fr a maximum f a 4 week supply at a time. Infrm the GP f the prescriptin details i.e. dse and frequency. Aviding phrases such as as directed Infrm the GP if the patient is receiving any additinal immunsuppressants r bilgic drugs and the GP shuld ensure that this infrmatin is added t the patient s medical recrd. Ensure that patient/ carer is trained in the administratin and dispsal f subcutaneus methtrexate (if applicable). Infrm the patient t reprt any side-effects t the Specialist r GP (Clinicians shuld refer t the individual drug Summary f Characteristics (SPCs) and current electrnic BNF fr full details f side effects). Bld Test Mnitring (See Summary f Bld Test mnitring schedule fr the different DMARDs Appendix 1) If the GP agrees t share care frm week 4 : Specialist shuld infrm patient that they will require regular bld tests whilst taking DMARD therapy. Specialist shuld prvide an initial prescriptin fr the first 6 weeks f therapy and issue the patient with 2 bld test frms (ne fr blds at week 2 and ne fr blds at week 4). Specialist t check the bld test results at week 2: If satisfactry, Specialist t advise patient t have a repeat bld test at week 4 and explain that the GP will take ver and that the GP shuld check the week 4 bld test results. If the week 4 results are satisfactry, the GP will then cntinue t prescribe and mnitr bld tests in the lng term as per the bld test schedule (appendix 1). Advise the patient that subsequent bld test mnitring frms shuld be btained frm their GP practice. If the GP agrees t share care frm when the patient is n a stable dse (typically frm arund 12 weeks): Specialist shuld infrm patient that they will require regular bld tests whilst taking DMARD therapy. Specialist shuld prvide prescriptins fr the DMARD medicatin until shared care with the GP is implemented. Specialist t issue bld test frms and t check the results fr the duratin f time until the GP agrees t share care. Once shared care is implemented, the GP will then cntinue t prescribe and mnitr bld tests in the lng term as per the bld test schedule (appendix 1). Advise the patient that subsequent bld test mnitring frms shuld be btained frm their GP.
4 Shared care Respnsibilities: Shared care can cmmence anytime frm 4 weeks after DMARD therapy has been initiated by the Specialist Team. (exact timing will vary depending n individual GP practises). Specialist Rheumatlgy Team GP Cnfirm that the GP will take ver the prescribing and bld test mnitring frm week 4 (r at ther time as agreed with GP). Infrm the GP f the frequency f bld tests that are required. (See Summary f bld test mnitring schedule Appendix 1) Agree hw the bld test results shuld be cmmunicated between the Specialist team and the GP (i.e. electrnically r paper cpy), ensuring that bld test results can be accessed in a timely manner by bth parties. Mnitr the patient s verall health and well-being. Update the patient s medical recrd t reflect the results f immunity screening and any vaccinatins given prir t DMARD therapy. Ensure that the patient s medical recrd is updated if the patients is als being prescribed an additinal immunsuppressant r bilgic agent by the Specialist Rheumatlgy team (as these are ften slely prescribed by secndary care clinicians). Prvide GP with advice n actin required in the event f abnrmal bld results / side effects when requested by the GP. NB: If a clinically urgent bld test abnrmality/ side effect ccurs, the Specialist Rheumatlgy Team shuld prvide advice within ne wrking day. NB: When advising the GP n a plan f actin t be taken, ensure that the length f time that will elapse befre the patient can be reviewed in the Specialist clinic is cmmunicated with the GP. Agree t take ver Prescribing fr the specified DMARD at an agreed date (can be anytime frm week 4 as per agreement). (NB: GPs shuld nte that sme patients, in particular thse cmmenced n methtrexate may nt yet be n a stable maintenance dse by week 4. In such cases, the Specialist team will prvide the GP with written details f the dse escalatin schedule.) Arrange t review the patient at Out-Patients as apprpriate Mnitr the patient s respnse t therapy. Infrm the GP f any changes made t the dsage / rute f administratin etc. At the agreed date (can be anytime frm week 4), agree t take ver bld test mnitring respnsibility at the specified frequency as directed by the Specialist team. (See Summary f bld test mnitring schedule Appendix 1) Mnitr the patient fr any side-effects t the specified DMARD therapy and infrm the GP if any ccur. Reprt any serius side-effects t the MHRA. (Refer t individual SPCs / electrnic BNF fr full details n side effects.) Check fr pssible drug interactins when prescribing any new medicatins r when stpping any cncurrent medicatins. (Refer t individual SPCs/ electrnic BNF) Ensure that the GP practice (and dispensaries, if a dispensing practice) cmputer sftware has the latest sftware updates relevant t the chsen DMARD, e.g. methtrexate alerts & prmpts. (as per NPSA advice) Decide when t stp therapy and infrm bth the patient and the GP. Mnitr the patient fr any side-effects t the specific DMARD therapy and refer back t the Specialist shuld any serius side-effect ccur. Reprt side effects t MHRA if apprpriate. (Refer t individual SPCs/ electrnic BNF fr full details n side effects.) Bld Tests : Reiterate the imprtance f attending fr regular bld test mnitring t the patient. Advise patients t attend fr a bld test apprximately. ne week befre their next prescriptin is due t ensure that the results can be reviewed befre the next prescriptin is requested fr issue. Ensure that bld test results are taken at the required frequency AND check the results prir t the issue f a subsequent prescriptin. (See Summary table f bld test mnitring frequency, Appendix 1 and individual drug prescribing infrmatin sheets)
5 Specialist Rheumatlgy Team GP Bld Tests: Cntinued Seek advice frm the Specialist as t whether mre frequent bld tests are required e.g. fllwing any dse adjustments, in certain patient grups e.g. thse with renal impairment, thse n mre than ne DMARD. Recrd bld test results in the GP medical recrd. Send a cpy f the bld tests t the Specialist fr infrmatin unless previusly agreed electrnic access is available. NB The Specialist will nt rutinely review the bld test results - this prcess is t allw the Specialist t review bld test results in the event when a GP cntacts them fr advice and als when reviewing the patient in utpatient clinic. Refer any patient wh fails t attend fr regular bld test mnitring back t the Specialist team. Cntact the Specialist fr advice with regards any actin that shuld be taken in the event f abnrmal bld results / side effects. NB: If a clinically urgent abnrmality, the Specialist Rheumatlgy Team shuld prvide advice within ne wrking day. Subsequent Prescriptins: Prvide subsequent prescriptins and ensure that repeat prescriptins requests fr all DMARDs (with the exceptin f Hydrxychlrquine) are retained separately fr prescriber review prir t authrisatin as they are regarded as high risk drugs which require a review f bld test results by the GP prir t issuing f a prescriptin. Prvide a maximum f 4 weeks supply at a time. This is applicable t all DMARDs. When prescribing methtrexate tablets, nly prescribe the 2.5mg strength tablets. (This has been agreed lcally as a way t reduce cnfusin and t reduce the risk f dispensing errrs.) Prescribe any cncmitant medicatin as specified by the Specialist (if applicable) e.g. fr patients n methtrexate, prescribe flic acid as directed by the Specialist team. Re-iterate any relevant advice e.g. infrmatin with regards cntraceptin / varicella zster immunity / alchl / waste dispsal - see the individual drug Prescribing drug infrmatin sheets (Appendix 2). Discuss drug therapy and management plan f any pregnant patients/any patients cnsidering pregnancy r anyne wishing t breastfeed with the Specialist Rheumatlgy team. Infectins Initiate prmpt anti-infectin treatment when indicated n the basis that the patient may be immunsuppressed t sme degree. During a serius infectin, DMARD therapy (except Hydrxychlrquine) shuld be temprarily discntinued until the patient has recvered frm the infectin. NB Serius infectin = warrants admissin t hspital r requires parenteral antimicrbial therapy. Fr patients wh are nn--immune and expsed t measles r chickenpx, cntact the Specialist Rheumatlgy team asap fr cnsideratin f apprpriate immunglbulin therapy. If patient cntracts chickenpx r shingles, cntact Specialist and treat with acyclvir.
6 Patient Respnsibilities Cmmunity Pharmacist Respnsibilities Discuss ptential benefits and side-effects f treatment with the Specialist and GP and share any cncerns they have in relatin t their treatment. Reprt any side-effects t the Specialist r GP. Reprt immediately, any breathlessness, dry cugh, whites f eyes becming yellw, severe itching f skin, rash, dark urine, infectins (including fever, chills r severe sre thrats), new unexplained bleeding r bruising, muth ulcers, vmiting and diarrhea (particularly if ccurs at the start f treatment, r if it is severe, at any stage in treatment). Be familiar with side effects and bld test mnitring requirements fr individual DMARDs. (Refer t Individual SpCs / electrnic BNF and Individual Prescribing drug infrmatin sheets.- Appendix 2) Check with patient that a recent bld test has been taken and the results checked by the GP / Specialist team befre dispensing DMARD medicatin. Cntact the prescribing clinician (GP / Specialist) if in any dubt abut the dsage prescribed r if any cncerns relating t bld test mnitring and bld test results Infrm all healthcare prfessinals (e.g. GP s, A&E clinicians, cmmunity pharmacists) that they are taking DMARD therapy and that regular bld test mnitring is being undertaken. Prvide adequate cunselling n the use f the specified DMARD(s). Advise patients t take flic acid as specified by the prescriber ensuring that flic acid is NOT taken n the same day as methtrexate (if applicable). Shw a cpy f the mst recent clinic letter cntaining current prescriptin details e.g. dse and frequency t the cmmunity pharmacist when presenting a prescriptin fr DMARD therapy. Be familiar with the NPSA guidance n methtrexate Participate in the mnitring f therapy (including having bld tests carried ut at agreed intervals) and assessment f utcmes. Ensure that a bld test is taken in advance f running ut f medicatin t allw time fr the results t cme back. Patients wh are nn-immune t measles and r varicella-zster shuld ntify GP and / r Specialist f any inadvertent expsure t a persn with measles / chicken px s that passive immunity can be given with the apprpriate immunglbulin therapy. T acknwledge advice given e.g. regarding cntraceptin, alchl, varicella, cyttxic waste dispsal. T use adequate cntraceptin and reprt any suspected pregnancy t the GP / Specialist Team. T infrm GP / Specialist f all medicines (including OTC preparatins) currently being taken. T fllw cyttxic waste dispsal prcedure as advised by Specialist team (if applicable)
7 BACK-UP ADVICE AND SUPPORT GP queries shuld be directed t the Rheumatlgy cnsultants. Patient queries shuld be directed t the Rheumatlgy Specialist Nurses All urgent requests shuld be answered within ne wrking day. CONTACT DETAILS The Lutn & Dunstable Hspital Cnsultants Dr Daniel Fishman, Dr Muhammed Nisar, Dr Tanya Baqai Dr Balaji Ramabhadran, Dr Vanessa Quick, Dr Marian Chan Tel: / Fax: Specialist Nurses Nicki Wd, Julie Begum, Sue O Cnnr : Nurse Advice Line: Bedfrd Hspital Cnsultants : Dr S Rae Specialist Nurse Marice Lenard Dr Eirini Giavri Nurse Advice Line : Dr M Wajed Tel: Tel: Secretary Fax: Written : Octber 2016 Updated : September 2018 Review date: September 2020
8 Appendix 1 Summary f Bld Mnitring Schedule fr DMARDs (Reference: The bld test schedule is based n current clinical practise and the BSR Guidelines - Guidelines fr disease-mdifying anti-rheumatic drug (DMARD) therapy (2017). Bld Tests required each time : FBC, creatinine/calculated GFR, ALT and/r AST and albumin DMARD (Single drug) Methtrexate (MTX) Azathiprine (AZA) Leflunmide (LEF) Bld Test Mnitring Schedule every 2 weeks until n a stable dse fr 6 weeks, then mnthly bld tests fr 3 mnths then every 12 weeks* lnger-term *Mre frequent mnitring is apprpriate fr patients at a higher risk f txicity. Sulfasalazine (SSZ) every 2 weeks until n a stable dse fr 6 weeks, then mnthly bld tests fr 3 mnths then every 12 weeks.* Other Mnitring Leflunmide Mnitr BP and weight at each mnitring visit. Azathiprine Assess baseline Thipurine methyltransferase (TPMT) status. *Mre frequent mnitring is apprpriate fr patients at a higher risk f txicity. Rutine bld test mnitring is nly required fr the first 12 mnths f therapy, after which time n rutine mnitring is needed. Mycphenlate (MMF) every 2 weeks until n a stable dse fr 6 weeks, then mnthly bld tests fr 3 mnths then every 12 weeks* lnger-term *Mre frequent mnitring is apprpriate fr patients at a higher risk f txicity. Hydrxychlrquine (HCQ) Cmbinatin therapy Leflunmide and Methtrexate (LEF/MTX) N rutine labratry mnitring required. every 2 weeks until n a stable dse fr 6 weeks, then mnthly bld tests lnger- term* Baseline frmal phthalmic examinatin (ideally including bjective retinal assessment e.g. using ptical cherence tmgraphy (OCT), within ne year f starting therapy. Annual eye assessment (ideally including OCT) if cntinued fr > 5 yrs. *Mre frequent mnitring is apprpriate fr patients at a higher risk f txicity. Patients wh have been stable fr 12 mnths can be reviewed by the Specialist team and cnsidered fr reduced frequency f mnitring n an individual basis. Other cmbinatins Mnitring f patients n mre than ne DMARD shuld be based n the DMARD which requires the mst frequent mnitring. Please nte : Fr all DMARDs : If the dse is increased at any time, bld test mnitring shuld increase t every 2 weeks until n a stable dse fr 6 weeks then mnthly fr 3 mnths, then revert back t previus schedule (as specified abve). *Mre frequent mnitring is apprpriate fr patients at a higher risk f txicity.
9 Appendix 2 Prescribing Infrmatin sheets fr GPs: Cntents: Methtrexate (ral r Subcutaneus injectin) (Fr patients under the care f the Lutn & Dunstable hspital nly) Methtrexate (ral r Subcutaneus injectin) (Fr patients under the care f Bedfrd Hspital nly) Sulfasalazine Leflunmide Azathiprine Mycphenlate Hydrxychlrquine
Shared Care Protocol for the prescribing and monitoring of maintenance doses of azathioprine in Inflammatory Bowel Disease
Bedfrdshire and Lutn Jint Prescribing Cmmittee Shared Care Prtcl fr the prescribing and mnitring f maintenance dses f azathiprine in Inflammatry Bwel Disease This prtcl applies t patients under the care
More informationShared Care Protocol for the prescribing and monitoring of maintenance doses of azathioprine in Inflammatory Bowel Disease
Apprved by the Bedfrdshire and Lutn Jint Prescribing Cmmittee (JPC) December 2013, Review date December 2016 Bedfrdshire and Lutn Jint Prescribing Cmmittee Shared Care Prtcl fr the prescribing and mnitring
More informationORAL AND PARENTERAL METHOTREXATE RHEUMATOLOGY LOCAL SAFETY MONITORING SCHEDULE
ORAL AND PARENTERAL METHOTREXATE RHEUMATOLOGY LOCAL SAFETY MONITORING SCHEDULE This lcal safety-mnitring schedule supprts clinicians under the Lcal Enhanced Service fr High Risk Drug Mnitring (frmerly
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationPain relief after surgery
Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationGeneric Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations
Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationThis standard operating procedure applies to stop smoking services provided by North 51.
Authr Name/Title Melanie McIlvar, Bid Develpment Manager Authr Signature Date: 4 th September 2017 Apprver Name/Title Jasn Shelley, Grup Directr f QA/RA Apprver Signature Date: 4 th September 2017 Issue
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationHospital Preparedness Checklist
Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. The United States is currently experiencing a natinwide utbreak f entervirus D68 (EV-D68) assciated with severe
More informationBritish Sign Language (BSL) Plan October 2018 Scottish Charity Regulator
British Sign Language (BSL) Plan 2018-2024 Octber 2018 Scttish Charity Regulatr Cntents Sectin 1: Intrductin and cntext 1.1 Intrductin 1.2 Our wrk and what we d Sectin 2: Our BSL Plan 2.1 Scttish Public
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More informationH1N1 Influenza 09 Guidance for Residential Aged Care
H1N1 Influenza 09 Guidance fr Residential Aged Care 11 June 2009 As knwledge abut H1N1 Influenza 09 develps, further advice will be prvided. Please check www.healthemergency.gv.au fr the latest infrmatin.
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. Over the last several mnths, the United States has experienced a natinwide utbreak f entervirus D68 (EV- D68) assciated
More informationAppendix 1 Example of Homely Remedy Policy
Appendix 1 Example f Hmely Remedy Plicy Hmely Remedy Plicy - EXAMPLE This plicy applies t (insert name f Care Hme) Definitin A hmely (r husehld) remedy is a medicinal prduct fr the shrt-term treatment
More informationLittle Angels Schoolhouse
Little Angels Schlhuse Sickness and Illness Plicy Aim Early Years Fundatin Stage Statutry Guidance The Prvider must prmte the gd health f the children, take necessary steps t prevent the spread f infectin
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationLow Molecular Weight Heparin Prescribing and Administration (Adults)
Clinical guideline Lw Mlecular Weight Heparin Prescribing and Administratin (Adults) The Natinal Patient Safety Agency issued guidance n ways f reducing dsing errrs when prescribing lw mlecular weight
More informationHead and neck cancers are often treated with radiotherapy. Radiotherapy can lead to faster rates of tooth decay and poor healing in the mouth.
DENTAL EXTRACTION This infrmatin aims t help yu understand the peratin, what is invlved and sme cmmn cmplicatins that may ccur. It may help answer sme f yur questins and help yu think f ther questins that
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.
Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationImmunisation and Disease Prevention Policy
Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries
More informationYou may have a higher risk of bleeding if you take warfarin sodium tablets and:
MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationInfluenza (Flu) Fact Sheet
Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder
More informationTick fever is a cattle disease caused by any one of the following blood parasites:
Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus
More informationRituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY
Rituximab PROTOCOL FOR PAEDIATRIC RHEUMATOLOGY 1. Backgrund and indicatins Rituximab is a mnclnal antibdy that wrks by remving B-cells (a type f white bld cell that prduce antibdies). The aim f the B cell
More informationMEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion
MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new
More informationCode of Conduct for Employees
Crprate Human Resurces Plicy Cntent Updated: 2016-06-22 Wrk Envirnment Plicy N: HR-01-09 Page 1 f 5 Apprval: 2014-09-24 Cde f Cnduct fr Emplyees POLICY STATEMENT The residents and businesses f the City
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationVaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE
Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationNHAIS SIS Communication
T: All NHAIS Key Users/Screening Managers Frm: Catherine Rberts SIS Request: T/14528 HSCIC Change Number: 15846 Date: 24/03/2015 Page 1 f 5 Impacted Applicatins: SD screen, Lab Links, MM screen, AJ-CD
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More informationPATIENT INFORMATION. (methotrexate) injection, for subcutaneous use
What is Rasuv? PATIENT INFORMATION RASUVO (ruh-soo-vh) (methtrexate) injectin, fr subcutaneus use Rasuv is a single-dse manually-triggered aut-injectr cntaining a prescriptin medicine, methtrexate. Methtrexate
More informationUniversity College Hospital. Pump school Starting on an insulin pump. Children and Young People s Diabetes Service
University Cllege Hspital Pump schl Starting n an insulin pump Children and Yung Peple s Diabetes Service 2 If yu wuld like this dcument in anther language r frmat, r require the services f an interpreter,
More informationACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.
27 March 2014 Prfessr Debra Picne Chief Executive Officer Australian Cmmissin n Safety and Quality in Health Care c/ Ms Jennifer Hill, Senir Prject Officer Level 5, 255 Elizabeth Street SYDNEY NSW 2000
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationDear Student, IMMUNIZATION RECORD INSTRUCTIONS
Dear Student, Welcme t the University f Chicag! The State f Illinis and University regulatins require students t prvide prf f required immunizatins prir t registratin fr classes. In rder t cmplete this
More informationDISTRIBUTION: ORGANIZATION WIDE APPROVED BY: VP COMPLIANCE
LAST REVISED: Page 1 f 5 POLICY CarePint Health (Baynne Medical Center, Christ Hspital, Hbken University Medical Center, CarePint Health Medical Grup, Garden State Healthcare Assciates, CarePint Health
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationAlcohol & Substance Misuse Policy. St Mary s CE Academy Trading Company. Date: Spring 2017 Date of Next Review: Summer 2018
St Mary s CE Academy Trading Cmpany Alchl & Substance Misuse Plicy Date: Spring 2017 Date f Next Review: Summer 2018 Signed by: Family Supprt Crdinatr Signed by: Grup Manager Alchl and Substance Misuse
More information2018 Medical Association Poster Symposium Guidelines
2018 Medical Assciatin Pster Sympsium Guidelines Overview The 3 rd Annual student-run Medical Assciatin f the State f Alabama Research Sympsium will take place n Friday and Saturday, April 13-14 at the
More informationRoActemra (tocilizumab) for Giant Cell Arteritis (GCA) subcutaneous (SC) formulation
RActemra (tcilizumab) fr Giant Cell Arteritis (GCA) subcutaneus (SC) frmulatin What yu shuld knw abut RActemra This brchure prvides key infrmatin t assist in the patient s understanding f the benefits
More informationCode of employment practice on infant feeding
Cde f emplyment practice n infant feeding An Emplyer s guide t: Sectin 69Y f the Emplyment Relatins Act 2000 Frewrd As Minister f Labur, I am pleased t publish the Cde f Emplyment Practice n Infant Feeding.
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationMEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID?
MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidmide) capsules What is the mst imprtant infrmatin I shuld knw abut REVLIMID? Befre yu begin taking REVLIMID, yu must read and agree t all f the instructins
More information77 WHO/IPA workshop on Immunisation
77 WHO/IPA wrkshp n Immunisatin cst/efficacy f either f them des nt justify their rutine use. Cntents f such diseases shuld be within the respnsibilities f the Epidemilgy Department. XVII INTERNATIONAL
More informationPATIENT INFORMATION. effective for the treatment of the flu in people with long-time (chronic) heart problems or breathing problems.
PATIENT INFORMATION capsules, fr ral use fr ral suspensin What is TAMIFLU? TAMIFLU is a prescriptin medicine used t: treat the flu (influenza) in peple 2 weeks f age and lder wh have had flu symptms fr
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More informationPROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS
PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards
More informationPART III: CONSUMER INFORMATION
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr ZERIT Stavudine This leaflet is Part III f a three-part Prduct Mngaph published when ZERIT was apprved fr sale in Canada and is designed specifically
More informationFDA Dietary Supplement cgmp
FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes
More informationUNIT 6. DEVELOPING THREAT/HAZARD-SPECIFIC ANNEXES
UNIT 6. DEVELOPING THREAT/HAZARD-SPECIFIC ANNEXES This page intentinally left blank. UNIT INTRODUCTION Visual 6.1 This unit presents infrmatin n annexes that shuld be included in a schl emergency peratins
More informationBenepali (etanercept): Brief training on additional Risk Minimisation Measures
Benepali (etanercept): Brief training n additinal Risk Minimisatin Measures Slide Deck fr Healthcare Prfessinal (HCP) Training Versin 9.0; 22 January 2016 UK/IE 1 Benepali (etanercept) This medicine is
More informationUse of sacubitril valsartan for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Shared Care Protocol
Oxfrdshire Clinical Cmmissining Grup Use f sacubitril valsartan fr the treatment f symptmatic chrnic heart failure with reduced ejectin fractin. Shared Care Prtcl This prtcl prvides prescribing and mnitring
More informationIf you have any doubts or queries about your medication, please contact your doctor or pharmacist.
Bayer plc Bayer Huse Strawberry Hill Newbury Berkshire RG14 1JA United Kingdm Telephne: +44 (0)1635 563 000 Facsimile: +44 (0)1635 563 393 Cmpany Web Site: http://www.bayer.c.uk Due t regulatry changes,
More information3903 Fair Ridge Drive, Suite 209, Fairfax, VA Harry Byrd Hwy, Suite 285, Ashburn, VA *How did you hear about our program?
3903 Fair Ridge Drive, Suite 209, Fairfax, VA 22033 44121 Harry Byrd Hwy, Suite 285, Ashburn, VA 220147 *Hw did yu hear abut ur prgram? Patient Histry Patient Name: First Middle: Last: Address: City: State:
More informationEvaluation of Hunter & New England HealthPathways
Evaluatin f Hunter & New England HealthPathways 2 General Practice & Ambulatry Care Activity General Practice MBS data: In 2013 there were 3.3 millin patient attendances t 730 GPs in the HML regin, a 5.6%
More informationI am having a Rotator Cuff Repair
I am having a Rtatr Cuff Repair A rtatr cuff repair is surgery t repair a trn tendn in the shulder. The rtatr cuff is a grup f muscles and tendns that frm a cuff ver the shulder jint. The muscles and tendns
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationFormulary and Prescribing Guidelines
Frmulary and Prescribing Guidelines SECTION 8: MANAGEMENT OF ACUTELY DISTURBED BEHAVIOUR 8. Rapid Tranquillisatin 8.1 Management f acutely disturbed ADULTS Befre cnsidering pharmaclgical measures: (see
More informationTELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT
TELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT Intrductin This is the Explanatry Statement fr the revised Cmmunicatins Alliance Telecmmunicatins Cnsumer Prtectins (TCP) Industry
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationMedical Student Immunization Requirements
Medical Student Immunizatin Requirements The State f Illinis cde, Reference: (110 ILCS 20) Cllege Student Immunizatin Act, requires students t prvide prf f immunity: Measles (Rubela), Mumps, Rubella (German
More informationDental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.
Dental Benefits Under the TeamstersCare Plan, yu and yur eligible dependents have three basic ptins when yu need dental care. Optin #1: TeamstersCare Dentists. Yu can use ur in-huse Charlestwn, Chelmsfrd,
More informationBP Thresholds for Medical Review
BP Threshlds fr Medical Review Wmen presents t GP pstnatally with high bld pressure r referred t GP by midwife GP t review patient n the same day if BP>150/100. If BP (dne by midwife) persistently 140-149/90-99,
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationMy Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)
My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made
More informationSection 6 Students School District No. 71 (Comox Valley)
Sectin 6 Students Schl District N. 71 (Cmx Valley) Administrative Prcedure 6011 MR2 Allergies and Anaphylaxis 1. Intrductin The Bard f Educatin expects schls t reasnably accmmdate students with medically
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationWARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least
More informationChapter 6: Impact Indicators
Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the
More informationPercutaneous Nephrolithotomy (PCNL)
Percutaneus Nephrlithtmy (PCNL) What is a percutaneus nephrlithtmy? is the mst effective f the cmmnly perfrmed prcedures fr kidney stnes. It is the best prcedure fr large and cmplex stnes. T perfrm this
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationAUTHORISED BY: CEO. Introduction. Whistle Blowing
GUIDELINE NAME: Field Cmplaints Disclsure Guidelines SECTION : Refer t Excel Guidelines list Dcument N: DISTRIBUTION: All Emplyees FIRST ISSUED: April 2013 DATE UPDATED: Dec 2014 ISSUED/UPDATED BY: Peple
More informationduring Last Days of Life
Unit 36: Supprting Individuals during Last Days f Life Unit reference number: F/616/7374 Level: 3 Unit type: Optinal Credit value: 4 Guided learning hurs: 32 Unit summary Prmting respnsive care in the
More informationIowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training
Iwa Early Peridic Screening, Diagnsis and Treatment Care fr Kids Prgram Prvider Training The Early Peridic Screening, Diagnsis and Treatment (EPSDT) Care fr Kids prgram is Iwa s Medicaid prgram fr children.
More informationDATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS
DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this
More informationHerbal Medicines: Traditional Herbal Registration
Herbal Medicines: Traditinal Herbal Registratin In the UK, cmpanies can nly sell herbal medicines with the apprpriate prduct licence, as fllws: A full marketing authrisatin based n the safety, quality
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More information